(Q35949084)

11 August 2017

1 reference

title

Cardiac toxicity of high-dose chemotherapy (English)

1 reference

11 August 2017

1 reference

Morandi P

1

1 reference

11 August 2017

Ruffini PA

2

1 reference

11 August 2017

Benvenuto GM

3

1 reference

11 August 2017

Raimondi R

4

1 reference

11 August 2017

Fosser V

5

1 reference

11 August 2017

language of work or name

English

0 references

publication date

1 February 2005

1 reference

Bone Marrow Transplantation

11 August 2017

published in

1 reference

11 August 2017

volume

35

1 reference

11 August 2017

issue

4

1 reference

11 August 2017

page(s)

323-334

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1704763

11 August 2017

exact match

0 references

cites work

Haemopoietic stem-cell transplantation: recent progress and future promise

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

Durable treatment-free remission after high-dose cyclophosphamide therapy for previously untreated severe aplastic anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

Cyclophosphamide and antithymocyte globulin to condition patients with aplastic anemia for allogeneic marrow transplantations: the experience in four centers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

Serum cardiac troponin I levels and ECG/Echo monitoring in breast cancer patients undergoing high-dose (7 g/m(2)) cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

Acute lethal carditis caused by high-dose combination chemotherapy. A unique clinical and pathological entity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

High dose cyclophosphamide therapy in solid tumors: Therapeutic, toxic, and immunosuppressive effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

Cyclophosphamide-induced cardiomyopathy. A report of two cases and review of the english literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

Cardiac involvement in bone marrow transplantation: serial changes in left ventricular size, mass and performance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

Evidence for sinoatrial blockade associated with high dose cytarabine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

QT dispersion as a predictor of acute heart failure after high-dose cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

Autologous transplantation for aggressive non-Hodgkin's lymphoma: results of a randomized trial evaluating graft source and minimal residual disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

University of Washington high-dose cyclophosphamide, mitoxantrone, and etoposide experience in metastatic breast cancer: unexpected cardiac toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

High-dose mitoxantrone + melphalan (MITO/L-PAM) as conditioning regimen supported by peripheral blood progenitor cell (PBPC) autograft in 113 lymphoma patients: high tolerability with reversible cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

High-dose chemotherapy (CTM) for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

Thiotepa-associated cardiomyopathy during blood or marrow transplantation: association with the female sex and cardiac risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

High-dose thiotepa and melphalan with hemopoietic progenitor support following induction therapy with epirubicin-paclitaxel-containing regimens in metastatic breast cancer (MBC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

High-dose ifosfamide is associated with severe, reversible cardiac dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

Myocardial ischemia associated with high-dose carmustine infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

High-dose intravenous melphalan: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

Paroxysmal atrial fibrillation after high-dose melphalan in five patients autotransplanted with blood progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

Melphalan 220 mg/m2 followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

Acute left ventricular failure following melphalan and fludarabine conditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

Allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results of a prospective multicentre study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

Cyclophosphamide toxicity. Characterising and avoiding the problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

Cardiac and pulmonary toxicity in patients undergoing high-dose chemotherapy for lymphoma and breast cancer: prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

Risk factors for doxorubicin-induced congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

Evaluation of long term cardiotoxicity after epirubicin containing adjuvant chemotherapy and locoregional radiotherapy for breast cancer using various detection techniques.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

Cardiac safety of liposomal anthracyclines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

Radiation-associated cardiovascular disease: manifestations and management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

Variability in determination of body weight used for dosing busulphan and cyclophosphamide in adult patients: results of an international survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

Impact of admission body weight and chemotherapy dose adjustment on the outcome of autologous bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

Impact of obesity in the setting of high-dose chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

Subclinical cardiotoxicity following adjuvant dose-escalated FEC, high-dose chemotherapy, or CMF in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

Natriuretic peptides during the development of doxorubicin-induced left ventricular diastolic dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

Early and late elevation of plasma atrial and brain natriuretic peptides in patients after bone marrow transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

Late effects of chemotherapy compared to bone marrow transplantation in the treatment of pediatric acute myeloid leukemia and myelodysplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

Late effects of intensive treatment for acute myeloid leukemia and myelodysplasia in childhood.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

Trastuzumab-associated cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

Monitoring of cardiac function by serum cardiac troponin T levels, ventricular repolarisation indices, and echocardiography after conditioning with fractionated total body irradiation and high-dose cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

Assessment of cardiotoxicity during haemopoietic stem cell transplantation with plasma brain natriuretic peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

7 January 2021

High-Dose Chemotherapy and Autologous Bone Marrow Transplantation Compared with MACOP-B in Aggressive B-Cell Lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

7 January 2021

The high-dose sequential (Milan) chemotherapy/PBSC transplantation regimen for patients with lymphoma is not cardiotoxic

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

7 January 2021

Cardiac complications after bone marrow transplantation. A report on a series of 63 consecutive transplantations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

7 January 2021

Cardiac changes with cyclophosphamide

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

7 January 2021

Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

7 January 2021

Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

7 January 2021

Cardiac toxicity following high-dose cyclophosphamide, cisplatin, and BCNU (STAMP-I) for breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

7 January 2021

Genomic screening and complications of hematopoietic stem cell transplantation: has the time come?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

7 January 2021

High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

7 January 2021

Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

7 January 2021

High dose cytosine arabinoside in the management of refractory acute leukaemia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

7 January 2021

Fatal cardiac toxicity in bone marrow transplant patients receiving cytosine arabinoside, cyclophosphamide, and total body irradiation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

7 January 2021

Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in patients with refractory lymphoma undergoing autologous bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

7 January 2021

Phase I clinical and pharmacokinetic study of high-dose mitoxantrone combined with carboplatin, cyclophosphamide, and autologous bone marrow rescue: high response rate for refractory ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

7 January 2021

Ifosfamide cardiotoxicity in humans

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

7 January 2021

VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

7 January 2021

High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

7 January 2021

Constrictive pericarditis post allogeneic bone marrow transplant for Philadelphia-positive acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

7 January 2021

Severe cardiac toxicity in hematological stem cell transplantation: predictive value of reduced left ventricular ejection fraction

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

7 January 2021

Cardiac systolic function before and after hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

7 January 2021

Doxorubicin clearance in the obese

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

7 January 2021

Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

7 January 2021

Electrocardiogram is very useful for predicting acute heart failure following myeloablative chemotherapy with hematopoietic stem cell transplantation rescue

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

7 January 2021

Cardiac toxicity of bone marrow transplantation: predictive value of cardiologic evaluation before transplant

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

7 January 2021

Value of the pretransplant evaluation in predicting toxic day-100 mortality among blood stem-cell and bone marrow transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

7 January 2021

The feasibility of high-dose chemotherapy in breast cancer patients with impaired left ventricular function.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

7 January 2021

Predictive value of left ventricular ejection fraction in stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

7 January 2021

Serious cardiac complications during bone marrow transplantation at the University of Minnesota, 1977-1997

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

7 January 2021

Predictive value of QT dispersion for acute heart failure after autologous and allogeneic hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

7 January 2021

Guidelines for clinical use of cardiac radionuclide imaging: A report of the American College of Cardiology/American Heart Association Task Force on assessment of diagnostic and therapeutic cardiovascular procedures (Committee on Radionuclide Imagin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

7 January 2021

Cardiac effects of high-dose epirubicin and cyclophosphamide in women with poor prognosis breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

7 January 2021

Early detection of anthracycline-induced cardiotoxicity by radionuclide angiocardiography

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

7 January 2021

Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

7 January 2021

Cardiac troponin I and N-terminal pro-brain natriuretic peptide in umbilical artery blood in relation to fetal heart rate abnormalities during labor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

7 January 2021

Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

7 January 2021

Late effects of treatment in survivors of childhood acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704763

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1704763

1 reference

11 August 2017

1 reference